Cannabis extracts produced different pain relief than pure THC-CBD blends at the same ratio
A whole-plant cannabis extract and a pure 1:1 THC:CBD mixture produced distinct pain-relief profiles and engaged different endocannabinoid targets in a rat model of diabetic neuropathy, despite having the same THC:CBD ratio.
Quick Facts
What This Study Found
When injected into the spinal fluid of rats with diabetic neuropathy, a type II cannabis extract and a 1:1 THC:CBD mix produced different antinociceptive responses despite equivalent THC content. The two preparations also engaged CB1, CB2 receptors, and TRPV1 channels differently.
Key Numbers
Four conditions tested: pure THC, pure CBD, 1:1 THC:CBD mix, balanced extract; three receptor systems evaluated (CB1, CB2, TRPV1)
How They Did This
Animal study using a rat model of diabetic neuropathy with intrathecal injection of pure THC, pure CBD, a 1:1 THC:CBD mix, and a balanced chemotype II cannabis extract. Receptor involvement assessed using CB1, CB2, and TRPV1 antagonists.
Why This Research Matters
Current medical cannabis prescribing relies heavily on THC:CBD ratios to predict effects. This study suggests that the full composition of an extract matters, not just its major cannabinoid ratio.
The Bigger Picture
The finding that same-ratio preparations produce different effects supports the entourage effect concept and challenges the practice of categorizing medical cannabis products primarily by THC:CBD ratio.
What This Study Doesn't Tell Us
Animal model with intrathecal (spinal) delivery, which does not reflect typical human routes of administration. Diabetic neuropathy model may not generalize to other pain types. Single extract tested.
Questions This Raises
- ?Which minor cannabinoids or terpenes in the whole-plant extract account for the different receptor engagement?
- ?Would these differences hold with oral or inhaled administration?
Trust & Context
- Key Stat:
- Same THC:CBD ratio, different pain relief profiles and receptor targets
- Evidence Grade:
- Animal study with controlled conditions and receptor-level analysis, but spinal delivery route and single extract tested limit clinical translation.
- Study Age:
- Published 2023
- Original Title:
- A type II cannabis extract and a 1:1 blend of Δ(9)-tetrahydrocannabinol and cannabidiol display distinct antinociceptive profiles and engage different endocannabinoid targets when administered into the subarachnoid space.
- Published In:
- Frontiers in pharmacology, 14, 1235255 (2023)
- Authors:
- Benredjem, Besma, Pineyro, Graciela
- Database ID:
- RTHC-04410
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Does the THC:CBD ratio predict how a cannabis product will work?
This animal study suggests not entirely. A whole cannabis extract and a pure 1:1 THC:CBD blend produced different pain relief responses and activated different receptor systems despite having the same ratio.
What is the entourage effect?
The idea that compounds in cannabis work together, so whole-plant extracts may produce different effects than isolated cannabinoids. This study provides evidence supporting that concept.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04410APA
Benredjem, Besma; Pineyro, Graciela. (2023). A type II cannabis extract and a 1:1 blend of Δ(9)-tetrahydrocannabinol and cannabidiol display distinct antinociceptive profiles and engage different endocannabinoid targets when administered into the subarachnoid space.. Frontiers in pharmacology, 14, 1235255. https://doi.org/10.3389/fphar.2023.1235255
MLA
Benredjem, Besma, et al. "A type II cannabis extract and a 1:1 blend of Δ(9)-tetrahydrocannabinol and cannabidiol display distinct antinociceptive profiles and engage different endocannabinoid targets when administered into the subarachnoid space.." Frontiers in pharmacology, 2023. https://doi.org/10.3389/fphar.2023.1235255
RethinkTHC
RethinkTHC Research Database. "A type II cannabis extract and a 1:1 blend of Δ(9)-tetrahydr..." RTHC-04410. Retrieved from https://rethinkthc.com/research/benredjem-2023-a-type-ii-cannabis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.